{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:22:23Z","timestamp":1772263343425,"version":"3.50.1"},"reference-count":36,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100012599","name":"Bethlehem Griffiths Research Foundation","doi-asserted-by":"crossref","award":["BGRF1810-1"],"award-info":[{"award-number":["BGRF1810-1"]}],"id":[{"id":"10.13039\/100012599","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian Government Research Training Program Scholarship"},{"name":"National Institute for Health Research University College London Hospitals Biomedical Research","award":["APP1161499"],"award-info":[{"award-number":["APP1161499"]}]},{"name":"National Health and Medical Research Council (NHMRC) Early Career Fellowship"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Arterial and venous thromboembolic events (TEEs) have been associated with intravenous Ig use, but the risk has been poorly quantified. We aimed to calculate the risk of TEEs associated with exposure to intravenous Ig.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included participants from UK Biobank recruited over 3 years, data extracted September 2020.<\/jats:p><jats:p>The study endpoints were incidence of myocardial infarction, other acute ischaemic heart disease, stroke, pulmonary embolism and other venous embolism and thrombosis.<\/jats:p><jats:p>Predictors included known TEE risk factors: age, sex, hypertension, smoking status, type 2 diabetes mellitus, hypercholesterolaemia, cancer and past history of TEE. Intravenous Ig and six other predictors were added in the sensitivity analysis.<\/jats:p><jats:p>Information from participants was collected prospectively, while data from linked resources, including death, cancer, hospital admissions and primary care records were collected retrospectively and prospectively.\u202f<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>14 794 of 502 492 individuals had an incident TEE during the study period. The rate of incident events was threefold higher in those with prior history of TEE (8 .7%) than those without previous history of TEE (3.0%).<\/jats:p><jats:p>In the prior TEE category, intravenous Ig exposure was independently associated with increased risk of incident TEE (OR=3.69 (95% CI 1.15 to 11.92), p=0.03) on multivariate analysis. The number needed to harm by exposure to intravenous Ig in those with a history of TEE was 5.8 (95% CI 2.3 to 88.3).<\/jats:p><jats:p>Intravenous Ig exposure did not increase risk of TEE in those with no previous history of TEE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Intravenous Ig is associated with increased risk of further TEE in individuals with prior history of an event with one further TEE for every six people exposed. In practice, this will influence how clinicians consent for and manage overall TEE risk on intravenous Ig exposure.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2022-328881","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T17:38:31Z","timestamp":1654882711000},"page":"876-885","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["IVIg-exposure and thromboembolic event risk: findings from the UK Biobank"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-3426","authenticated-orcid":false,"given":"Mahima","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-9212","authenticated-orcid":false,"given":"Laura Jayne","family":"Bonnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-7767","authenticated-orcid":false,"given":"Elspeth Jane","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Paul","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisling S","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2023052203450705000_93.8.876.1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"2023052203450705000_93.8.876.2","unstructured":"Blumberg L . FDA Safety Communication : New boxed warning for thrombosis related to human immune globulin, 2013: 1\u20133."},{"key":"2023052203450705000_93.8.876.3","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"2023052203450705000_93.8.876.4","unstructured":"National Institute for Health and Care E . Identification and assessment of cardiovascular disease risk, 2021."},{"key":"2023052203450705000_93.8.876.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39609.449676.25"},{"key":"2023052203450705000_93.8.876.6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5694\/mja2.50004","article-title":"New guidelines from the thrombosis and haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism","volume":"210","author":"Tran","year":"2019","journal-title":"Med J Aust"},{"key":"2023052203450705000_93.8.876.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60404-8"},{"key":"2023052203450705000_93.8.876.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60924-6"},{"key":"2023052203450705000_93.8.876.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001779"},{"key":"2023052203450705000_93.8.876.10","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx246"},{"key":"2023052203450705000_93.8.876.11","first-page":"252","volume-title":"International statistical classification of diseases and related health problems ICD-10: instruction manual","volume":"2","year":"2016"},{"key":"2023052203450705000_93.8.876.12","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1002\/sim.6986","article-title":"Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model","volume":"35","author":"Collins","year":"2016","journal-title":"Stat Med"},{"key":"2023052203450705000_93.8.876.13","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9736"},{"key":"2023052203450705000_93.8.876.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00341-9"},{"key":"2023052203450705000_93.8.876.15","doi-asserted-by":"publisher","DOI":"10.1175\/1520-0493(1950)078&lt;0001:VOFEIT&gt;2.0.CO;2"},{"key":"2023052203450705000_93.8.876.16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jamia\/ocz228","article-title":"A tutorial on calibration measurements and calibration models for clinical prediction models","volume":"27","author":"Huang","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"2023052203450705000_93.8.876.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"2023052203450705000_93.8.876.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647552"},{"key":"2023052203450705000_93.8.876.19","doi-asserted-by":"publisher","DOI":"10.1159\/000081465"},{"key":"2023052203450705000_93.8.876.20","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068335.01620.9D"},{"key":"2023052203450705000_93.8.876.21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","article-title":"Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products","volume":"42","author":"Germishuizen","year":"2014","journal-title":"Biologicals"},{"key":"2023052203450705000_93.8.876.22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10325"},{"key":"2023052203450705000_93.8.876.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01287.x"},{"key":"2023052203450705000_93.8.876.24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.13580","article-title":"IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans","volume":"204","author":"Nguyen","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2023052203450705000_93.8.876.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh297"},{"key":"2023052203450705000_93.8.876.26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s11739-019-02150-z","article-title":"Intravenous immunoglobulin therapy: a snapshot for the internist","volume":"14","author":"Vitiello","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2023052203450705000_93.8.876.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.253"},{"key":"2023052203450705000_93.8.876.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4363"},{"key":"2023052203450705000_93.8.876.29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017160"},{"key":"2023052203450705000_93.8.876.30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(15)31026-3","article-title":"Global burden of CVD: focus on secondary prevention of cardiovascular disease","volume":"201 Suppl 1","author":"Bansilal","year":"2015","journal-title":"Int J Cardiol"},{"key":"2023052203450705000_93.8.876.31","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2023052203450705000_93.8.876.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31791-X"},{"key":"2023052203450705000_93.8.876.33","unstructured":"Committee for medicinal products for human use EMA . Core SPC for human normal immunoglobulin for intravenous administration (IVIg, 2004."},{"key":"2023052203450705000_93.8.876.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.046"},{"key":"2023052203450705000_93.8.876.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.05.035"},{"key":"2023052203450705000_93.8.876.36","doi-asserted-by":"publisher","DOI":"10.1017\/S0714980813000366"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-328881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T10:49:06Z","timestamp":1684752546000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-328881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,7,14]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/jnnp-2022-328881"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-328881","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}